Tumefactive multiple sclerosis and fingolimod Immunotherapies and unintended consequences Our knowledge of the substantial complexities of the immune system and understanding of the immunopathogenesis of autoimmune diseases are increasing at such a rapid pace that it is impossible for the nonimmunologist to stay abreast of the field. However, there are 2 general principles that are important for clinicians to keep in mind. One is that the immune system regulates itself. The effector arm of the adaptive immune system consists of subsets of lymphocytes that recognize and respond to non-self antigens expressed by infectious agents and malignant cells. Other subsets of lymphocytes regulate the effector arm of the immune system, thereby fine-tuning and limiting responses. A second principle is that autoimmune diseases, such as multiple sclerosis (MS), result from a failure of regulation of lymphocytes capable of reacting to self-antigens. Thus autoimmunity is conceived of as a loss of active tolerance to self-antigens related to activation of effector autoreactive lymphocytes and reduction in activity of regulatory lymphocytes. Much is known about the cellular subsets and molecules involved in autoimmune diseases, allowing for rational development of immunotherapies. No better example of this exists than in the expanding armamentarium of immunotherapies for the treatment of MS.
In this issue of Neurology ® , Pilz et al. 1 report on a person with MS who developed tumefactive lesions 6 months after starting fingolimod. As they report, there are several other published case reports of tumefactive MS occurring in association with fingolimod. Given the rarity of tumefactive MS and the fact that it generally occurs very early in the course of disease, 2 it seems likely that fingolimod led to the development of the tumefactive lesions. These cases as well as other reports of fingolimod appearing to increase disease activity in some patients with MS suggest that fingolimod can have a paradoxical effect on MS. 3 Fingolimod is a sphingosine-1-phosphate (S1P) partial agonist that downregulates expression of S1P receptors on lymphocytes and a variety of other cells. 4 By inhibiting expression of S1P receptors on lymphocytes, fingolimod impedes trafficking of lymphocytes out of lymph nodes. This results in a substantial reduction of T and B cells in the blood. The therapeutic effect of fingolimod in MS thereby results, at least in part, from the inhibition of the egress of encephalitogenic autoreactive lymphocytes out of the lymph nodes. Importantly, fingolimod does not affect subsets of lymphocytes uniformly. For instance, fingolimod inhibits circulation of CD41 cells more than CD81 cells, resulting in a reversal of the CD41/CD81 ratio within the blood. 5 It also inhibits the circulation of T-naive and effector cells more than T effector memory cells. More research is needed to delineate the effects of fingolimod on subsets of lymphocytes and to determine whether the effects of fingolimod on lymphocyte subsets might vary among individuals.
How might fingolimod cause tumefactive MS lesions? One possibility is that lymphocyte subsets in some people treated with fingolimod might be shifted in a way that promotes MS disease activity rather than inhibiting it. Pilz and colleagues present for the first time evidence to suggest that this may happen. In their patient, they observed the expected changes in peripheral lymphocyte phenotypes, with a significant reduction in CD41/CD81 T-cell ratio and reduction in CD191 B cells. Importantly, there were other changes that were not expected. There was a marked predominance of T effector memory cells, particularly CD81 effector memory cells, in the peripheral blood, and a concentration of the CD81 memory effector cells in the CSF. In addition, CD81 effector cells, while low in the peripheral blood, were relatively increased in the CSF. These subset shifts were not observed in a small number of other people with MS treated with fingolimod. The concentration of CD81 effector cells within the CNS compartment is of importance since these cells can release perforin and thereby be cytotoxic. It is conceivable that activation of the CD81 effector memory cells within the CNS generated the CD81 effector cells, and these cells might in turn have led to the development of tumefactive lesions.
